Skip to main content
Oncodesign Precision Medicine S.A logo

Oncodesign Precision Medicine S.A — Investor Relations & Filings

Ticker · ALOPM ISIN · FR001400CM63 LEI · 969500ZDX1IY47LDL876 Euronext Access Plus Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2023-10-05 Capital/Financing Update
Country FR France
Listing Euronext Access Plus ALOPM

About Oncodesign Precision Medicine S.A

https://www.oncodesign.com/

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. The company's mission is to develop and provide innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis in cancer. OPM focuses on creating value through a patient-centric and translational approach, collaborating with clinicians, service providers, and experts. Its core activities are centered on discovering new treatments for resistant and metastatic cancers, aiming to identify the most effective therapeutic pathways for patients.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that Oncodesign Precision Medicine (OPM) has secured a €6 million bank financing agreement from several regional banks. The core subject is a new financing/fundraising activity, which directly aligns with the definition of 'Capital/Financing Update'. The document details the amount, the purpose (continuing clinical development), and the impact on the cash position. This fits the 'CAP' code much better than a general 'RNS' or 'ER'.
2023-10-05 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that Oncodesign Precision Medicine (OPM) has secured a 6 million euro bank financing agreement from several regional banks. The key focus is on fundraising, capital structure, and how this non-dilutive financing supports clinical development (OPM-101) and technology development. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and financing activities.
2023-10-05 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release announcing positive interim results from a Phase 1 clinical study (OPM-101) in healthy volunteers. It details study completion milestones, safety data, pharmacokinetics, and regulatory approval to proceed to the next phase (MDA). This type of announcement, focusing on key clinical trial updates and financial/operational progress outside of mandatory periodic financial reports (like 10-K or IR), is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical trial update, it falls under the general category of corporate news. However, given the options, this is a specific operational update that often accompanies or precedes an earnings release, but it is not a full financial report (10-K, IR) or a transcript (CT). It is a direct announcement of operational progress and results. Since it is not a formal regulatory filing like a 10-K or a general regulatory announcement (RNS), and it is not a presentation (IP) or a management discussion (MDA), the most fitting category for a press release detailing operational/clinical progress is often the Earnings Release (ER) category, as these announcements frequently serve the same purpose of informing the market of recent performance/developments, even if not strictly quarterly financials. Alternatively, it could be RNS if it were a mandatory filing, but as a press release detailing clinical progress, ER is a strong fit for market-sensitive operational news. Q4 2023
2023-10-02 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated October 2, 2023, announcing positive interim results from a Phase 1 clinical trial (SAD part completed, moving to MAD part) for a drug candidate (OPM-101). It details clinical progress, safety profile, and future plans, including regulatory approval from ANSM. This type of announcement, focusing on the immediate release of key periodic financial/clinical results, aligns best with an Earnings Release (ER) or, given the specific focus on clinical trial results which are often released outside standard quarterly cycles, it could be considered a general announcement. However, since it is a detailed announcement of clinical trial progress and results, it is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It is a specific announcement of results. Since there is no specific code for 'Clinical Trial Results Announcement', and it is a formal announcement of results, 'ER' (Earnings Release) is the closest fit for a periodic/key result announcement, although 'RNS' (Regulatory Filings) is a strong fallback. Given the structure and content (key highlights followed by management commentary), it functions as an 'Earnings Release' for clinical milestones, which often use the ER code in databases when a specific clinical update code is unavailable. It is not a short announcement pointing to an attached report, so RPA/RNS is less likely than ER for the core content type. Q4 2023
2023-10-02 French
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport de gestion' (Management Report) for the period ending June 30, 2023, for Oncodesign Precision Medicine (OPM). It includes a 'mot du président', detailed business descriptions, strategy, and operational highlights. While it contains management commentary, it is a comprehensive report covering the interim period (first half of 2023) and includes financial context and operational analysis, fitting the definition of an Interim/Quarterly Report (IR). FY 2023
2023-09-29 French
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 1% confidence The document is a short announcement titled "OPM met à disposition son rapport financier du 1er semestre 2023" (OPM makes available its financial report for the first half of 2023). It explicitly states that the 'rapport financier semestriel' (half-yearly financial report) has been filed and is available on the company website. Since the document itself is short (3122 characters) and its primary function is to announce the publication of a report rather than being the comprehensive report itself (which would typically be an Interim Report (IR) or Annual Report (10-K)), it fits the definition of a Report Publication Announcement (RPA).
2023-09-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.